01Core principlesThe concepts and mechanisms needed to understand the subject.
T1 is an anatomical depth category: invasion is confined to mucosa in T1a or enters submucosa in T1b. It does not by itself prove that local treatment is curative. Safe endoscopic cure also depends on site-specific lymph-node risk, differentiation, ulceration, size, lymphovascular invasion and complete vertical and horizontal clearance. An intact resection specimen can therefore convert an apparently early lesion into a surgical-risk cancer.
Expert assessment uses high-resolution and image-enhanced endoscopy to mark lateral extent and identify synchronous disease. EMR captures a lesion with a snare, often after lifting or banding. ESD dissects through submucosa for controlled en-bloc removal. Piecemeal excision may clear visible tissue but can make lateral margins uninterpretable, weakening confidence that treatment was curative.
The pathologist reports depth, differentiation, ulceration, horizontal and vertical margins, lymphovascular invasion and tumour-specific criteria. Favourable Barrett T1a adenocarcinoma can proceed to residual-Barrett ablation and surveillance. For gastric adenocarcinoma, en-bloc R0 pT1a differentiated cancer without lymphovascular invasion is very-low risk when non-ulcerated at any size or ulcerated at 30 mm or less. Piecemeal resection or a positive horizontal margin in an otherwise curative lesion is a local persistence risk managed by endoscopic surveillance or re-treatment; a positive vertical margin, lymphovascular invasion or submucosal depth greater than 500 micrometres is high-risk and requires complete staging and surgical MDT assessment.
Key points
- Endoscopic treatment is appropriate only when invasion and nodal risk are sufficiently low for local excision to provide oncological cure.
- Enhanced imaging defines lesion borders and morphology; biopsies establish neoplasia but repeated sampling can create fibrosis that complicates definitive resection.
- En-bloc resection is preferred when feasible because orientation and margins determine curative status.
- Endoscopic mucosal resection suits many small accessible lesions; endoscopic submucosal dissection permits en-bloc removal of larger lesions but needs advanced expertise and carries greater perforation risk.
- For visible Barrett neoplasia, resect the lesion then ablate residual Barrett epithelium when indicated to reduce metachronous field disease.
- Pathology after resection is the decision point: curative features lead to surveillance, while adverse depth, margins or lymphovascular invasion lead to cancer MDT discussion.
02Mechanisms and patternsImportant relationships and how to distinguish them.
A well-demarcated superficial abnormality without deep ulceration may be suitable for endoscopic resection.
Fibrosis or invasion can prevent lifting and signal technical difficulty or deeper disease.
A focal abnormality within Barrett mucosa requires resection for histological stage before field ablation.
Deep invasion, lymphovascular spread or a positive vertical margin makes local therapy potentially non-curative.
Extensive oesophageal mucosal removal increases stricture risk and changes consent and prevention planning.
03Interpreting evidenceInformation, measurements and their limitations.
Consider the information, its meaning and its limitations before deciding what follows.
- 01
Expert enhanced endoscopy - Why
- Define lesion margins, morphology and synchronous disease.
- Interpretation and limitations
- Use the pattern to select EMR, ESD, surgery or further staging rather than ablating an uncharacterised nodule.
- 02
Diagnostic biopsies - Why
- Confirm dysplasia or carcinoma before definitive treatment.
- Interpretation and limitations
- For a potentially endoscopically resectable lesion, one or two targeted biopsies are usually sufficient before expert resection; repeated sampling can cause fibrosis and compromise lifting.
- 03
Endoscopic resection - Why
- Remove the lesion and produce an oriented staging specimen.
- Interpretation and limitations
- En-bloc pathology is most reliable for margin and depth assessment; fragmentation reduces certainty.
- 04
Definitive histopathology - Why
- Determine whether local excision meets curative criteria.
- Interpretation and limitations
- Interpret site-specific criteria. In gastric cancer, separate a local-risk piecemeal or horizontal-margin result from high-risk vertical-margin, lymphovascular or deep-submucosal disease.
- 05
Selective nodal staging - Why
- Assess regional nodes when invasion risk exceeds a purely mucosal lesion.
- Interpretation and limitations
- EUS cannot exclude microscopic nodes, and adverse resection histology may justify surgery despite negative imaging.
04Applied reasoningWorked examples connecting principles to decisions.
01Worked case: Barrett noduleUse resection pathology to prove local cureA 59-year-old with a long Barrett segment has a 14 mm raised nodule containing high-grade dysplasia on one targeted biopsy; expert imaging shows no second visible lesion.+
- 1At an expert session, enhanced imaging defines the nodule and excludes a second visible lesion; the endoscopist chooses en-bloc endoscopic mucosal resection before any field ablation.
- 2The oriented specimen shows intramucosal T1a adenocarcinoma, well differentiated, with clear lateral and deep margins and no lymphovascular invasion, meeting the MDT’s local-curative criteria.
- 3The specialist service ablates the residual flat Barrett epithelium in staged treatment, preserving the resection result as the basis for avoiding oesophagectomy.
- 4Verify eradication at protocolled follow-up: biopsies show no residual dysplasia, the resection site is healed and the patient has no treatment-related stricture symptoms.
02Worked case: curative gastric ESDUse the specimen to confirm very-low nodal riskExpert imaging shows a 24 mm non-ulcerated differentiated intramucosal gastric adenocarcinoma suitable for endoscopic submucosal dissection.+
- 1Proceed to expert en-bloc ESD without routine CT, EUS or PET-CT because the lesion has no feature suggesting deep invasion and is suitable for endoscopic resection.
- 2The oriented specimen is pT1a, differentiated, R0 at horizontal and vertical margins, non-ulcerated and has no lymphovascular invasion.
- 3Classify the result as very-low-risk curative resection, so gastrectomy and lymphadenectomy are not added solely because invasive adenocarcinoma was present.
- 4Verify healing and absence of residual or metachronous lesion at high-quality surveillance endoscopy 4 months later, then continue annual surveillance under MAPS III.
03Gastric non-curative patternsSeparate local persistence from lymph-node riskA 16 mm differentiated intramucosal gastric cancer is removed piecemeal with a positive horizontal margin but clear vertical margin and no lymphovascular invasion.+
- 1Confirm there is no submucosal cancer at the cut edge and that all other features meet curative or very-low-risk criteria.
- 2Classify this as local-risk resection and plan expert endoscopic surveillance or re-treatment because the concern is residual mucosal disease.
- 3Do not apply that route to a positive vertical margin, lymphovascular invasion or invasion more than 500 micrometres into submucosa; those are high-risk findings requiring staging and surgical MDT review.
- 4Verify the actual local-risk case at repeat endoscopy: residual tissue is resected, pathology is clear and the patient enters the specified surveillance programme.
04Worked case: post-ESD painExclude perforationHours after gastric ESD, a patient develops persistent severe pain, tachycardia and guarding.+
- 1Stop oral intake and assess the patient urgently rather than attributing pain to insufflation.
- 2Obtain appropriate CT imaging and start resuscitation and antimicrobials when contamination is suspected.
- 3Use expert endoscopic closure, drainage or surgery according to defect and physiology.
- 4Confirm clinical recovery and healing before advancing intake.
05Checking understandingVerify the reasoning, revisit uncertainties and apply feedback.
- Review final resection pathology at a specialist MDT before declaring cure.
- Monitor immediately for bleeding, pain, fever, dyspnoea and peritoneal or mediastinal signs.
- Track dysphagia after extensive oesophageal treatment for developing stricture.
- Use scheduled high-quality endoscopy after eradication to detect recurrence or metachronous lesions.
- Record whether margins were interpretable and whether resection was en bloc or piecemeal.
06Special situationsVariants, exceptions and circumstances that change the usual approach.
Resection is a staging test
The excised specimen often changes the presumed depth and therefore the entire treatment plan.
Ablation cannot stage a nodule
Destroying visible neoplasia without a specimen loses invasion and margin information.
Local cure depends on nodal biology
A clear mucosal margin is insufficient when lymphovascular or deep submucosal invasion predicts occult nodes.
Field treatment follows focal treatment
In Barrett neoplasia, removal of the lesion and eradication of remaining metaplastic mucosa solve different risks.
07Common pitfallsFrequent interpretation and management errors.
- 01
Ablating a visible Barrett lesion without prior resection.
- 02
Calling piecemeal removal curative when margins cannot be reconstructed.
- 03
Ignoring lymphovascular invasion because the endoscopic defect looks clear.
- 04
Dismissing persistent post-resection pain without evaluating perforation.